Understanding the Impact of CMS Prescription Drug Negotiations on Patient Out-of-Pocket Costs
Affordability of prescription medicines continues to be a topic of concern in the U.S. healthcare system. Therefore, there is broad interest in understanding the current and future trends in patient out-of-pockets costs as they are impacted by market dynamics and policy changes, including the implementation of the Centers for Medicare and Medicare Services (CMS) Drug Negotiation Program as part of the Inflation Reduction Act. Government price negotiations will impact drug prices but are unlikely to lead to consistent reductions in patient cost sharing, with many patients experiencing negligible savings or even potentially higher out-of-pocket costs due to countervailing factors and unintended consequences.
The Proliferation of Innovation Over Time: Considerations for Drug Expansions under the Medicare Drug Price Negotiation Program
The Inflation Reduction Act’s Medicare Drug Price Negotiation Program represents a paradigm shift in drug pricing policy in the U.S. For drugs selected for maximum fair price (MFP) setting, the window for achieving returns is likely to condense as the MFP setting comes into effect at 9 years post-initial FDA approval for small molecules and 13 years for biologics. This changing dynamic suggests that clinical development post-initial approval may be adversely impacted. Understanding the historical trends in this development is crucial for assessing the potential effects of this policy on innovation and implications for stakeholders.
Policy Shifts Reshaping Biopharma: IRA, PBM Reform and Beyond
U.S. healthcare policy is undergoing rapid change, with wide-ranging consequences for biopharma strategy, pricing, and competitiveness. From government efforts to control drug costs to shifts in vaccine policy to PBM reform, manufacturers face a complex and evolving policy landscape. At the same time, evolving trade policies have created a climate of uncertainty for biopharma companies, making it difficult to manage supply chains and make long-term plans.
Watch this session for a breakdown of the policy developments that matter most for biopharma leaders—what’s changing, how it may impact the industry, and the strategies companies are deploying to adapt.
NACD PSW: The Board’s Advocacy Role in Healthcare - PBM Impact
National Association of Corporate Directors: What employers should know about PBMs
Pioneer Life Sciences Institute Policy Update: IRA Impact on Patient Access to Life-Saving Medicines & 340B Website Update
Pioneer Senior Fellows Dr. William Smith, PhD and Dr. Robert Popovian, PharmD, highlight updates and new data in the Institute's first-of-its-kind PLSI 50-state mapping tool and database on 340B that uncovers the troubling way in which hospitals and covered entities leverage unlimited pharmacy contracts under the program. Drs. Smith and Popovian also share a preview of a forthcoming PLSI tool that will investigate and track the impact of the Inflation Reduction Act on patient access and prescription drug formularies.
Will Patients Benefit from IRA's Maximum Fair Price?
Insightful discussion on the impact of the Inflation Reduction Act's maximum fair price on patients
Public Health = Fiscal Health: A Special National Tax Payers Union Webinar Series
Panelists, Eric Hargan, former Deputy Secretary of the Department of Health and Human Services, and Dr. Robert Popovian, Senior Health Policy Fellow at the Progressive Policy Institute, will lend their expertise to discussions ranging from FDA approval processes, to march-in rights, to the Inflation Reduction Act's pharmaceutical provisions. Moderated by NTU President Pete Sepp, this session promises a lively discussion about the nexus between health care and taxpayers.
Pioneer Institute's Virtual Policy Briefing: Value & Pricing Models for Gene Replacement Therapies
Pioneer Institute's webinar on gene replacement therapy (GRT) featured esteemed panelists Dr. Robert Popovian, Senior Visiting Health Policy Fellow at Pioneer Institute; Dr. William Smith, Senior Fellow & Director of the Pioneer Life Sciences Initiative at Pioneer Institute; and Dr. Anne M. Sydor, Director of Research Development and Communications at the Global Healthy Living Foundation.
Advancing Vaccine Policy: Live from the World Vaccine Congress
Join Dr. Robert Popovian and Ben Blanc for a special live episode from the World Vaccine Congress in Washington, DC, where they delve into the latest developments in vaccine policy and economic research. This episode spotlights the congress's role as a vital hub for collaboration and innovation in the vaccine industry.
Webinar: Impact of Formulary Exclusions on Individual Patients
In this webinar you will learn how formulary exclusions impact a patient's care and well-being. You will also learn about original research conducted by the GHLF researchers regarding formulary exclusions and our GHLF's plans to raise awareness concerning this important issue with policymakers.
Accumulators and Maximizer Ponzi Scheme
Big or Small, Red or Blue – States With Laws Protecting Patient Assistance Programs Have Not Seen Health Insurance Premium Hikes
340B Program - No Longer Serving Patients
340B drug discount program has veered from its original mission to help low-income patients access medicine, and has instead grown into a profit revenue stream for hospitals.
State of Wisconsin - Governors Task Force On Reducing Prescription Drug Prices
How PBMs inflate healthcare spending in the U.S.
Out of Pocket Pirates!
How PBMs steel patient assistance program funding to benefit their bottom line.